Clinical Trial: Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539610) titled 'Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors' on Jan. 15.

Brief Summary: Evaluation of Sup19 CAR-T cells in cases where previous CD19-targeted therapy has failed or where CD19 Evaluation of Safety and Efficacy in the Treatment of Low-Grade Hematological Malignancies: A Prospective, Single-Arm Clinical Study Research

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: B-Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia/Lymphoma

Intervention: BIOLOGICAL: Sup19 CAR-T

The use of Sup19 CAR-T...